<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512470730</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512470730</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Charcot Prize Lecture</subject></subj-group></article-categories>
<title-group>
<article-title>Piet Mondrian’s trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Steinman</surname><given-names>Lawrence</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Axtell</surname><given-names>Robert C</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barbieri</surname><given-names>Donald</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bhat</surname><given-names>Roopa</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brownell</surname><given-names>Sara E</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de Jong</surname><given-names>Brigit A</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512470730">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dunn</surname><given-names>Shannon E</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512470730">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Grant</surname><given-names>Jacqueline L</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Han</surname><given-names>May H</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ho</surname><given-names>Peggy P</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuipers</surname><given-names>Hedwich F</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kurnellas</surname><given-names>Michael P</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ousman</surname><given-names>Shalina S</given-names></name>
<xref ref-type="aff" rid="aff4-1352458512470730">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rothbard</surname><given-names>Jonathan B</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512470730">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512470730"><label>1</label>Department of Neurology and Neurological Sciences, Stanford University, USA</aff>
<aff id="aff2-1352458512470730"><label>2</label>Department of Neurology (HP935), Radboud University Nijmegen Medical Centre, The Netherlands</aff>
<aff id="aff3-1352458512470730"><label>3</label>Department of Immunology, University of Toronto, Canada</aff>
<aff id="aff4-1352458512470730"><label>4</label>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Canada</aff>
<author-notes>
<corresp id="corresp1-1352458512470730">Lawrence Steinman, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA. Email: <email>steinman@stanford.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>14</lpage>
<history><date date-type="received"><day>13</day>
<month>11</month>
<year>2012</year></date>
<date date-type="accepted"><day>18</day>
<month>11</month>
<year>2012</year></date></history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Four questions were posed about multiple sclerosis (MS) at the 2011 Charcot Lecture, Oct. 22, 2011. 1. <italic><underline>The Male/Female Disparity:</underline></italic> Why are women developing MS so much more frequently than men? 2. <italic><underline>Neuronal and Glial Protection:</underline></italic> Are there guardian molecules that protect the nervous system in MS? 3. <italic><underline>Predictive Medicine:</underline></italic> With all the approved drugs, how can we rationally decide which one to use? 4. <italic><underline>The Precise Scalpel vs. the Big Hammer for Therapy:</underline></italic> Is antigen-specific therapy for demyelinating disease possible? To emphasize how our views on the pathogenesis and treatment of MS are evolving, and given the location of the talk in Amsterdam, Piet Mondrian’s progressive interpretations of trees serve as a heuristic.</p>
</abstract>
<kwd-group>
<kwd>Multiple sclerosis</kwd>
<kwd>Charcot Lecture</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Here we pose four questions that are relevant to our understanding of multiple sclerosis (MS). For each, we shall look at the evolution of Piet Mondrian’s paintings of a solitary tree. As we follow the evolution in these paintings from representational to Cubist, we see that our understanding of MS is also a mere process, and that we have a long way to go before it is “complete.”</p>
<sec id="section1-1352458512470730">
<title>Question 1: The female/male disparity: Why are women developing MS so much more frequently than men?</title>
<p>The first example is Mondrian’s 1908 painting of the Red Tree,<sup><xref ref-type="bibr" rid="bibr1-1352458512470730">1</xref></sup> a highly representational portrait of a branching tree, devoid of leaves, with a red trunk and leaves perhaps representing the changing of seasons from autumn to winter (<xref ref-type="fig" rid="fig1-1352458512470730">Figure 1</xref>).</p>
<fig id="fig1-1352458512470730" position="float">
<label>Figure 1.</label>
<caption>
<p><italic>Piet Mondrian, AVOND (evening): The Red Tree, 1908-10</italic>. © 2013 Mondrian/Holtzman Trust c/o HCR International USA.<sup><xref ref-type="bibr" rid="bibr1-1352458512470730">1</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig1.tif"/></fig>
<p>We are witnessing a remarkable evolution in the ratio of females compared to males who are developing MS. Ebers and colleagues demonstrated that there has been a substantial increase in the ratio of females to males over the past 50 years in Canada<sup><xref ref-type="bibr" rid="bibr2-1352458512470730">2</xref></sup> and in the United States (US).<sup><xref ref-type="bibr" rid="bibr3-1352458512470730">3</xref></sup> Interactions between the environment and genes were considered the most likely basis for this increase. We have explored the molecular basis for this striking dimorphism in susceptibility to autoimmune neuro-inflammation in females, and find that a set of gene-encoding receptors, the peroxisome proliferator-activated receptors (PPARs), are involved. The PPARs act as transcription factors and are strongly influenced by sex hormones, lipids and fatty acids.</p>
<p>Shannon Dunn, now at the University of Toronto, has led a number of studies showing that in various experimental models of MS, collectively known as experimental autoimmune encephalomyelitis (EAE), the PPARs play a major role. In EAE, females are generally highly susceptible to EAE in particular genetic strains of mice, while males are relatively resistant. In 2007 she showed that in male mice where PPARα was deleted, the males became much more highly susceptible to EAE than in their wild-type counterparts (<xref ref-type="fig" rid="fig2-1352458512470730">Figure 2</xref>).<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref></sup></p>
<fig id="fig2-1352458512470730" position="float">
<label>Figure 2.</label>
<caption>
<p>Deletion of peroxisome proliferator-activated receptors (PPAR)α increases the susceptibility of male mice to experimental autoimmune encephalomyelitis (EAE).<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref></sup> Shown are results of two EAE experiments. *Indicates a significant difference from the control group (<italic>p</italic>&lt;0.05), as determined by Mann-Whitney statistics. WT: wild type. From Dunn et al.<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig2.tif"/></fig>
<p>Dunn and colleagues also showed that female mice had a much stronger T helper cell type 1 (Th1) response than their male counterparts, with higher production of interferon-γ after antigen stimulation of T lymphocytes.<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref></sup> When the gene encoding PPARα was deleted from males, these males made a Th1 response equivalent to females. PPARα acted as a brake on Th1 immunity in males. In these experiments we learned that males express more PPARα protein in their T cells than females, and that this disparity could be suppressed with castration whereas in females more PPARα is expressed with administration of 5α-dihydrotestosterone.<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref></sup></p>
<p>Dunn and colleagues then demonstrated that the PPARα agonist gemfibrozil (Lopid®) suppresses EAE,<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref></sup> a finding that Lovett-Racke and colleagues had made earlier.<sup><xref ref-type="bibr" rid="bibr5-1352458512470730">5</xref></sup> In 2012 Dunn and her colleagues published studies extending these findings to humans. Healthy human females make much stronger Th1 responses than human males, while males make stronger Th17 responses than females. In concordance with the studies in mice, androgens enhanced PPARα expression in humans. She also found that PPARγ regulates Th17 responses in humans.<sup><xref ref-type="bibr" rid="bibr6-1352458512470730">6</xref></sup> Dunn was able to translate experiments from mouse to man on how males and females respond much differently to antigenic stimulation.</p>
<p>These studies may begin to help explain why there is an increasing incidence of MS in females. One might argue that the increase in MS in females must be due to some factor in the environment. It is hard to imagine that females are “evolving” so rapidly that one might attribute this phenomenon to a genetic factor. We suggest the most likely environmental influence is the increased “fat” and increased caloric intake in the female diet. The set of receptors influenced by fats and by sex hormones is of course found in the remarkable PPAR family.<sup><xref ref-type="bibr" rid="bibr6-1352458512470730">6</xref></sup> The work of Dunn and colleagues may lead to practical therapies modulating PPAR activity as she and Lovett-Racke and colleagues already have demonstrated.<sup><xref ref-type="bibr" rid="bibr4-1352458512470730">4</xref>
<xref ref-type="bibr" rid="bibr5-1352458512470730"/>–<xref ref-type="bibr" rid="bibr6-1352458512470730">6</xref></sup></p>
</sec>
<sec id="section2-1352458512470730">
<title>Question 2: Neuronal and glial protection: Are there guardian molecules that protect the nervous system in MS?</title>
<p>In 1911 Mondrian painted The Grey Tree, devoid of color (<xref ref-type="fig" rid="fig3-1352458512470730">Figure 3</xref>). The Grey Tree was much more abstract than the Red Tree as Mondrian began to experiment with Cubism. We are learning that MS is not only a disease of white matter, as we were taught in medical school in the 1960s, but is clearly a disease involving gray matter as well. We sought to identify molecules that are produced by both neurons and glia, and that serve to protect the brain from inflammatory and degenerative damage. Here I shall review some of the progress in identifying some of these molecules, including the neurotransmitter γ-aminobutyric acid (GABA), the small heat shock protein, αB crystallin, and some of the endogenous lipids found in the myelin sheath.</p>
<fig id="fig3-1352458512470730" position="float">
<label>Figure 3.</label>
<caption>
<p><italic>Piet Mondrian, The Grey Tree, 1911</italic>. © 2013 Mondrian/Holtzman Trust c/o HCR International USA.<sup><xref ref-type="bibr" rid="bibr7-1352458512470730">7</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig3.tif"/></fig>
<p>In order to identify and to study various molecules that are produced in gray and white matter in response to the destruction that occurs in MS brain lesions, we have analyzed well-defined lesions from the brains of MS patients with various technologies, including robotic sequencing of MS libraries and an analysis of RNA transcripts with gene microarrays.<sup><xref ref-type="bibr" rid="bibr8-1352458512470730">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458512470730">9</xref></sup> We have compared RNA transcripts and proteins with proteomic analysis of the same laser-captured microdissected lesions.<sup><xref ref-type="bibr" rid="bibr10-1352458512470730">10</xref>,<xref ref-type="bibr" rid="bibr11-1352458512470730">11</xref></sup> We have taken these studies even deeper, exploring MS lesions with lipidomic mass spectrometry and lipid-based autoantibody arrays<sup><xref ref-type="bibr" rid="bibr12-1352458512470730">12</xref>,<xref ref-type="bibr" rid="bibr13-1352458512470730">13</xref></sup> to pinpoint the lipids that are under attack in MS. From all these analyses we have identified a group of unique molecules with promise for attenuating inflammation and degeneration in relapsing–remitting MS (RRMS) and in progressive forms of MS. Here we shall focus on a few clear examples, the role of GABA as an inhibitor of inflammation, the role of αB crystallin as a guardian molecule in a swathe of diseases, and the protective properties of certain lipids of the myelin sheath.</p>
<p>Proteomic<sup><xref ref-type="bibr" rid="bibr10-1352458512470730">10</xref></sup> and microarray studies<sup><xref ref-type="bibr" rid="bibr9-1352458512470730">9</xref></sup> indicated that the machinery to synthesize glutamic acid decarboxlase and to degrade GABA, GABA transaminase, was present in acute as well as chronic MS lesions. Further, receptors for GABA were also present in both white and gray matter lesions from the MS brain.<sup><xref ref-type="bibr" rid="bibr9-1352458512470730">9</xref></sup> Transporter systems for GABA reuptake were seen in acute plaques.<sup><xref ref-type="bibr" rid="bibr10-1352458512470730">10</xref></sup> Remarkably, these elements were also found in cellular components of the immune system: Antigen-presenting cells responded to application of GABA in electrophysiologic studies using patch clamping.<sup><xref ref-type="bibr" rid="bibr14-1352458512470730">14</xref></sup> We asked whether modulation of the GABA system might influence various animal models of EAE. Increasing GABA activity with various pharmacologic mediators suppressed EAE (<xref ref-type="fig" rid="fig4-1352458512470730">Figure 4</xref>). We could isolate these effects on the immune system with adoptive transfer experiments, where immune cells are exposed to pharmacologic mediators and then transferred into recipients that have never been exposed to the drug of interest. Of potential interest for translational application, approved drugs like topiramate that modulate the GABA system suppress the degree of paralysis and inflammation in EAE.</p>
<fig id="fig4-1352458512470730" position="float">
<label>Figure 4.</label>
<caption>
<p>γ-aminobutyric acid (GABA)ergic agents ameliorate experimental autoimmune encephalomyelitis (EAE). (A–C) SJL/J mice were immunized with 100 μg of proteolipid protein (PLP) 139–151 in complete Freund's adjuvant (CFA). Graphs represent prevention of EAE (A) by oral treatment with topiramate (100 mg/kg/day) or vigabatrin (400 mg/kg/day) starting at the time of immunization, as indicated by the arrow; and treatment of established EAE (B and C) by oral topiramate (100 mg/kg/day) or vigabatrin (400 mg/kg/day) starting at the peak of disease, as indicated by the arrow. Data represent clinical scores, as described in Materials and methods, mean ± SEM, representative of two independent experiments, <italic>n</italic> = 10 per group. *<italic>p</italic> &lt; 0.05, Mann-Whitney analysis. In B and C, mice were treated daily except during days 32–42, as indicated by the solid bar, when they were treated every three days. Reprinted with permission from Bhat et al.<sup><xref ref-type="bibr" rid="bibr14-1352458512470730">14</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig4.tif"/></fig>
<p>One of the big surprises in our research over the past decade was the discovery that αB crystallin, produced in copious amounts in MS lesions, is a guardian molecule.<sup><xref ref-type="bibr" rid="bibr15-1352458512470730">15</xref>
<xref ref-type="bibr" rid="bibr16-1352458512470730"/><xref ref-type="bibr" rid="bibr17-1352458512470730"/>–<xref ref-type="bibr" rid="bibr18-1352458512470730">18</xref></sup> Van Noort had shown in 1995 that αB crystallin is produced in white matter and is actually targeted by the adaptive immune system.<sup><xref ref-type="bibr" rid="bibr19-1352458512470730">19</xref>,<xref ref-type="bibr" rid="bibr20-1352458512470730">20</xref></sup> In a series of experiments over the past decade, Ousman and colleagues first showed that in mice where αB crystallin was deleted there was worsened inflammation and paralysis in the EAE model. Administration of αB crystallin actually attenuated disease and down-regulated the production of pro-inflammatory cytokines in both the Th1 and Th17 pathways. Kurnellas and Rothbard have now shown that αB crystallin binds the pro-inflammatory mediators in plasma.<sup><xref ref-type="bibr" rid="bibr17-1352458512470730">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458512470730">18</xref></sup></p>
<p>In a series of collaborations with our colleagues in ophthalmology and surgery, we have shown that αB crystallin is protective in other conditions such as optic nerve ischemia, stroke and myocardial infarction.<sup><xref ref-type="bibr" rid="bibr21-1352458512470730">21</xref>
<xref ref-type="bibr" rid="bibr22-1352458512470730"/>–<xref ref-type="bibr" rid="bibr23-1352458512470730">23</xref></sup> αB crystallin forms amyloid aggregates. Remarkably, other amyloids found in MS lesions such as amyloid precursor protein play a protective role. Grant and colleagues showed that Aβ 1-40 and Aβ 1-42 are protective in EAE, reducing inflammation and reversing paralytic signs.<sup><xref ref-type="bibr" rid="bibr24-1352458512470730">24</xref></sup> In all cases where amyloids have been deleted in gene knockout mice, EAE is worsened. We first described this with αB crystallin,<sup><xref ref-type="bibr" rid="bibr15-1352458512470730">15</xref></sup> then Aβ,<sup><xref ref-type="bibr" rid="bibr24-1352458512470730">24</xref></sup> while others have shown that EAE is worsened in knockouts of prion protein<sup><xref ref-type="bibr" rid="bibr25-1352458512470730">25</xref></sup> and Tau.<sup><xref ref-type="bibr" rid="bibr26-1352458512470730">26</xref></sup> The penumbra of a stroke is larger in αB crystallin knockouts,<sup><xref ref-type="bibr" rid="bibr22-1352458512470730">22</xref></sup> and focal brain trauma is worsened in knockouts of the amyloid precursor protein.<sup><xref ref-type="bibr" rid="bibr27-1352458512470730">27</xref></sup> The amyloid molecules produced in the brain in response to stress in a variety of pathologies including MS may be imbued with protective properties. These molecules may be actually converted into therapeutics for MS, in both the relapsing–remitting and progressive manifestations of the disease.</p>
<p>We have further analyzed MS pathology with lipidomics and lipid arrays.<sup><xref ref-type="bibr" rid="bibr12-1352458512470730">12</xref>,<xref ref-type="bibr" rid="bibr13-1352458512470730">13</xref></sup> Ho and colleagues discovered that there are lipids in the myelin sheath that are imbued with protective qualities. Administration of certain naturally occurring phospholipids was beneficial in reducing paralysis in models of EAE. Administration of these phospholipids reduced pro-inflammatory cytokine production and has potential as a therapeutic for relapsing–remitting and progressive forms of MS.</p>
</sec>
<sec id="section3-1352458512470730">
<title>Question 3: Predictive medicine: With all the approved drugs, how can we rationally decide which one to use in a particular individual?</title>
<p>In <xref ref-type="fig" rid="fig5-1352458512470730">Figure 5</xref>, The Flowering Apple Tree,<sup><xref ref-type="bibr" rid="bibr28-1352458512470730">28</xref></sup> painted in 1912, Mondrian has evolved his depiction of trees to an even more Cubist interpretation. It is a wonder that our brains perceive a “tree” in this representation with only subtle representational cues. But as we acknowledge these subtle cues, the rising verticality of the “trunk” and the characteristic horizontality of the branches, we learn that this is all that we need to convince ourselves, that is, our brains, that this is a “tree.” Steinman was fortunate to have studied with David Hubel and Torsten Weisel in medical school, where he first became familiar with the neurophysiology of perception of art in the brain, and also first performed and published experiments on GABA.<sup><xref ref-type="bibr" rid="bibr29-1352458512470730">29</xref></sup></p>
<fig id="fig5-1352458512470730" position="float">
<label>Figure 5.</label>
<caption>
<p><italic>Piet Mondrian, Flowering Appletree, 1912</italic>. © 2013 Mondrian/Holtzman Trust c/o HCR International USA.<sup><xref ref-type="bibr" rid="bibr28-1352458512470730">28</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig5.tif"/></fig>
<p>Just as our brains can discern what is a tree and what is not, we therefore ask whether there are rational algorithms to determine which therapeutic is most suitable for any particular patient. As treating neurologists we are blessed with a situation now where we can choose between multiple orally active drugs as well as injectable drugs for treatment of RRMS. But how can we make rational decisions when choosing among them?</p>
<p>Axtell and colleagues made the seminal observation that in the EAE models interferon (IFN)β ameliorates paralysis and inflammation in Th1 versions of EAE driven by IFNγ, while in Th17 versions of EAE, IFNβ worsens disease. This was shown with recombinant mouse IFNβ and with Rebif in these EAE models.<sup><xref ref-type="bibr" rid="bibr30-1352458512470730">30</xref></sup> Axtell and colleagues showed that when EAE is successful in treating EAE, interleukin (IL)-27, IL-10 and IL-4 are all produced, contributing to the anti-inflammatory activity of IFNβ. These studies were translated to human Th1 and Th17 T cells.<sup><xref ref-type="bibr" rid="bibr30-1352458512470730">30</xref></sup> In a small study of 26 RRMS patients conducted in collaboration with Polman and Killestein in Amsterdam, some patients with very high levels of IL-17F at baseline, before taking IFNβ, were non-responders over the next two years with breakthrough relapses.<sup><xref ref-type="bibr" rid="bibr30-1352458512470730">30</xref></sup> Patients with levels above 100 pg/ml of IL-17F were non-responders in this cohort.</p>
<p>In one follow-up study involving 118 patients, Axtell and colleagues in collaboration with Bushnell and colleagues showed that there was no correlation between IL-17F levels and non-responsiveness to IFNβ. Of note, in this study half the patients from the original cohort of 237 were excluded by the definitions of responder/non-responder that were chosen in that study.<sup><xref ref-type="bibr" rid="bibr31-1352458512470730">31</xref></sup> Levels above 200 pg/ml were seen in only one patient, a non-responder.</p>
<p>A number of studies point to some degree of confirmation of the Axtell<sup><xref ref-type="bibr" rid="bibr32-1352458512470730">32</xref></sup> study. In collaboration with Hartung and scientists from Bayer, a study of patients taking Betaseron was undertaken. Serum samples were analyzed from 239 randomly selected patients treated with IFNβ-1b 250 μg for more than two years in the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) study. We found that none of the patients without any clinical or radiological disease activity under IFNβ-1b demonstrated baseline IL-17F values above 200 pg/mL, whereas eight (4.4%) of the patients with at least some disease activity showed such values (<xref ref-type="fig" rid="fig6-1352458512470730">Figure 6</xref>).<sup><xref ref-type="bibr" rid="bibr32-1352458512470730">32</xref></sup></p>
<fig id="fig6-1352458512470730" position="float">
<label>Figure 6.</label>
<caption>
<p>In patients taking Betaseron, baseline levels of interleukin (IL)-17F above 200 pg/ml were 100% accurate in choosing non-responders. From Hartung et al.<sup><xref ref-type="bibr" rid="bibr32-1352458512470730">32</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig6.tif"/></fig>
<p>In these studies extremes of outcome were of value in predicting who may or may not respond to IFNβ. The notion that a test on a single analyte may be informative for only a minority of patients is a matter that we might need to accept. However, expanding the algorithm to include measurement of multiple analytes may be more informative. Axtell and colleagues in collaboration with Lin at Pfizer showed that high levels of IL-7 and low levels of IL-17F were predictive of responsiveness to IFNβ.<sup><xref ref-type="bibr" rid="bibr33-1352458512470730">33</xref></sup> Sweeney and colleagues showed that high levels of IL-27 predicted responsiveness to IFNβ.<sup><xref ref-type="bibr" rid="bibr34-1352458512470730">34</xref></sup> Dhib-Jalbut and colleagues showed that “in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12 months, IL-17 levels were significantly higher at month 6 (<italic>p</italic> = 0.036) in relapsing subjects.”<sup><xref ref-type="bibr" rid="bibr35-1352458512470730">35</xref></sup></p>
<p>The most significant breakthrough in predictive testing thus far is for mitigating the risk of development of progressive multifocal leukoencephalopathy (PML) after taking Tysabri for two years or more. In 1992 in a collaboration with Yednock, Steinman laboratory showed that α4 integrin was the main molecule involved in homing to the brain. We have recently recounted the details of the critical experiment that led to the identification of this particular integrin in lymphocyte homing to the brain, and the subsequent development of the drug Natalizumab (Tysabri) (<xref ref-type="fig" rid="fig7-1352458512470730">Figure 7</xref>).<sup><xref ref-type="bibr" rid="bibr36-1352458512470730">36</xref>
<xref ref-type="bibr" rid="bibr37-1352458512470730"/><xref ref-type="bibr" rid="bibr38-1352458512470730"/>–<xref ref-type="bibr" rid="bibr39-1352458512470730">39</xref></sup></p>
<fig id="fig7-1352458512470730" position="float">
<label>Figure 7.</label>
<caption>
<p>Natalizumab blocks homing in multiple sclerosis (MS). In (A) α4integrin binds to vascular cell adhesion molecule 1 (VCAM1). In (B) natalizumab, a humanized antibody to α4integrin blocks binding of lymphocytes to VCAM-1 in inflamed brain endothelium, preventing lymphocyte entry into the central nervous system.<sup><xref ref-type="bibr" rid="bibr39-1352458512470730">39</xref></sup> <xref ref-type="fig" rid="fig7-1352458512470730">Figure 7</xref> reproduced with permission from the <italic>Journal of Cell Biology</italic>.<sup><xref ref-type="bibr" rid="bibr39-1352458512470730">39</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig7.tif"/></fig>
<p>Natalizumab, a humanized antibody to α4 integrin, was developed and approved for use in RRMS in 2004. A terrible setback occurred in 2005 when patients treated with natalizumab developed PML, with fatalities in some patients. Now a predictive test for antibodies to the John Cunningham virus (JCV) has been developed and approved that enables us to predict who is “at risk” and who is not at risk for development of this dreaded complication.<sup><xref ref-type="bibr" rid="bibr38-1352458512470730">38</xref>
<xref ref-type="bibr" rid="bibr39-1352458512470730"/>–<xref ref-type="bibr" rid="bibr40-1352458512470730">40</xref></sup> More than 100,000 individuals with RRMS have now taken natalizumab.<sup><xref ref-type="bibr" rid="bibr38-1352458512470730">38</xref>
<xref ref-type="bibr" rid="bibr39-1352458512470730"/>–<xref ref-type="bibr" rid="bibr40-1352458512470730">40</xref></sup></p>
</sec>
<sec id="section4-1352458512470730">
<title>Question 4: The precise scalpel vs the big hammer for therapy: Is antigen-specific therapy for demyelinating disease possible?</title>
<p>The 1912 Composition Trees II (<xref ref-type="fig" rid="fig8-1352458512470730">Figure 8</xref>) reflects Mondrian’s further evolution to a Cubist interpretation of a tree. Reduction of the concept of a tree to a succession of precise cube-like elements would be taken even further later in Mondrian’s career. In parallel we ask whether MS will be treated with much more precision, with therapeutics that are much more discerning, than those ‘Big Hammers’ that are currently the subject of intense interest in the MS community.</p>
<fig id="fig8-1352458512470730" position="float">
<label>Figure 8.</label>
<caption>
<p><italic>Piet Mondrian, Composition Trees 2, 1912–13</italic>. © 2013 Mondrian/Holtzman Trust c/o HCR International USA.<sup><xref ref-type="bibr" rid="bibr41-1352458512470730">41</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig8.tif"/></fig>
<p>We refer to the “big hammers” as those drugs that impact wide swathes of the immune system. This would apply to two promising monoclonal antibodies: anti-CD20, which targets most B cell populations, and anti-CD52, which targets T cells, B cells and other monocytes. Monoclonal antibodies to targeting CD20 and CD52 have shown great promise in phase 2 and phase 3 trials.<sup><xref ref-type="bibr" rid="bibr42-1352458512470730">42</xref>,<xref ref-type="bibr" rid="bibr43-1352458512470730">43</xref></sup> Other drugs that might be considered big hammers include natalizumab, which blocks homing of cells bearing α4 integrin (see <xref ref-type="fig" rid="fig7-1352458512470730">Figure 7</xref>), and fingolimod, which targets sphingosine-1-phosphate receptors and blocks lymphocyte egress from lymph nodes, inducing lymphopenia.<sup><xref ref-type="bibr" rid="bibr38-1352458512470730">38</xref>
<xref ref-type="bibr" rid="bibr39-1352458512470730"/>–<xref ref-type="bibr" rid="bibr40-1352458512470730">40</xref>,<xref ref-type="bibr" rid="bibr44-1352458512470730">44</xref></sup> Both natalizumab<sup><xref ref-type="bibr" rid="bibr38-1352458512470730">38</xref>
<xref ref-type="bibr" rid="bibr39-1352458512470730"/>–<xref ref-type="bibr" rid="bibr40-1352458512470730">40</xref></sup> and fingolimod<sup><xref ref-type="bibr" rid="bibr44-1352458512470730">44</xref></sup> are highly effective in RRMS.</p>
<p>There are other approaches with new drugs that may be far less disruptive that show promise. The most advanced is BG-12, a derivative of fumarate from the Kreb’s Cycle that has shown positive results in reducing relapse rate and disease progression in RRMS.<sup><xref ref-type="bibr" rid="bibr45-1352458512470730">45</xref></sup> Older drugs like Vitamin D is another product that might be used adjunctively with other approved medicines. Use of Vitamin D may already be common practice. Other drugs may have promise if repurposed in combination with approved drugs. These include approved drugs like the angiotensin receptor blockers,<sup><xref ref-type="bibr" rid="bibr46-1352458512470730">46</xref>,<xref ref-type="bibr" rid="bibr47-1352458512470730">47</xref></sup> angiotensin-converting enzyme inhibitors,<sup><xref ref-type="bibr" rid="bibr46-1352458512470730">46</xref></sup> and statins.<sup><xref ref-type="bibr" rid="bibr48-1352458512470730">48</xref>,<xref ref-type="bibr" rid="bibr49-1352458512470730">49</xref></sup> One of us (LS) has started a company, Transparency Life Sciences, to use Web-based clinical trial design to repurpose already approved drugs for clinical trials in MS.<sup><xref ref-type="bibr" rid="bibr50-1352458512470730">50</xref></sup></p>
<p>Ever more elusive in these days of the big hammers would be the use of a precise scalpel to treat MS. Around the globe a few approaches are being tried in patients. Martin and Miller et al. are using antigen-coupled lymphocytes against a few peptide sequences on myelin,<sup><xref ref-type="bibr" rid="bibr51-1352458512470730">51</xref></sup> Wraith and colleagues are attempting peptide-based therapies from a few myelin proteins,<sup><xref ref-type="bibr" rid="bibr52-1352458512470730">52</xref></sup> and Selmaj and colleagues are attempting dermal administration of myelin antiens.<sup><xref ref-type="bibr" rid="bibr53-1352458512470730">53</xref></sup> All of these trials show some promise in the early stages. We have taken DNA vaccines through a phase 2 clinical trial in RRMS. In collaboration with Bar-Or, we have observed antigen-specific tolerance at the T cell level, with a reduction in myelin-specific T cells that produce IFN-γ in response to myelin basic protein lasting for a year, following nine weekly injections of a DNA tolerizing vaccine to myelin basic protein (see <xref ref-type="fig" rid="fig9-1352458512470730">Figure 9</xref>). Responses to tetanus toxoid were not impaired.<sup><xref ref-type="bibr" rid="bibr54-1352458512470730">54</xref></sup> The significance of this preservation of responses to tetanus toxin would be that such a specific approach would leave intact our ability to fight potential pathogens like JCV.</p>
<fig id="fig9-1352458512470730" position="float">
<label>Figure 9.</label>
<caption>
<p>Reduction of T cell responses to myelin basic protein and to proteolipid protein for 50 weeks, following nine weekly injections of a tolerizing DNA vaccine to myelin basic protein in one patient (54). Responses to tetanus toxoid were not impaired. Here the “myelin basic protein (MBP) – and proteolipid protein (PLP)-specific T-cell proliferative response decreased in response to BHT-3009 is shown. Proliferation was measured using a dye dilution method with the vital dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE). Peripheral blood mononuclear cells were incubated with a variety of antigens and controls, but for simplicity, only the responses to tetanus toxoid (TT), MBP83-99 peptide, and a PLP peptide mix are shown. The upper three panels correspond to the baseline response; the middle three, to the week nine response; and the bottom three, to the week 50 response. Proliferating interferon (IFN)-γ-positive CD4+ T cells are shown in the upper left quadrant of each fluorescent-activated cell sorter plot. Numbers in red indicate the percentage of cells in each quadrant. A dramatic decrease in IFN-γ-positive cells specific for MBP and PLP is demonstrated by week nine and persists to week 50. Importantly, the response to TT is unchanged with dosing, confirming the antigen-specific nature of BHT-3009.”<sup><xref ref-type="bibr" rid="bibr54-1352458512470730">54</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig9.tif"/></fig>
<p>In the phase 2 clinical trial<sup><xref ref-type="bibr" rid="bibr55-1352458512470730">55</xref></sup> with antigen-specific vaccines in MS, “treatment with the lower dose (0.5 mg) of BHT-3009 for 44 weeks nearly attained the primary end point for reduction of the rate of new enhancing magnetic resonance imaging (MRI) lesions (<italic>p</italic> &lt; 0.07) and achieved several secondary end points including reduction of the rate of enhancing MRI lesions from weeks eight to 48 (<italic>p</italic> &lt; 0.05). Immunological data in a preselected subgroup of patients indicated that treatment with 0.5 mg induced antigen-specific immune tolerance.”</p>
<p>One of the daunting problems facing those who are attempting antigen-specific therapy in MS is the large diversity of adaptive immune responses to myelin proteins<sup><xref ref-type="bibr" rid="bibr55-1352458512470730">55</xref></sup> and lipids.<sup><xref ref-type="bibr" rid="bibr12-1352458512470730">12</xref>,<xref ref-type="bibr" rid="bibr13-1352458512470730">13</xref></sup> A more sensible place to test the concept of antigen-specific tolerance might be in neuromyelitis optica (NMO), where the major target of the immune response is directed to aquaporin 4 (AQP4). Bennett and Verkman and colleagues have designed a passive immune therapy for NMO through engineering an AQP4 antibody so that it would not fix complement. In models of NMO the approach is promising and is heading for the clinic.<sup><xref ref-type="bibr" rid="bibr56-1352458512470730">56</xref>,<xref ref-type="bibr" rid="bibr57-1352458512470730">57</xref></sup> We are undertaking an active approach to tolerizing the immune system to AQP4 with a tolerizing DNA vaccine encoding AQP4.<sup><xref ref-type="bibr" rid="bibr58-1352458512470730">58</xref></sup></p>
</sec>
<sec id="section5-1352458512470730">
<title>Coda</title>
<p>Until we cure MS in all its manifestations it is perhaps premature to give awards. The Charcot Prize should be viewed as recognition of an immense international effort to understand the pathogenesis of MS and to develop effective treatments, and finally perhaps even take preventive measures to stop MS from occurring. After all, more than 65 years ago, we began to achieve this goal for eradication of poliomyelitis, a devastating neurological disease, with only a few cases per year worldwide today. Like Mondrian’s paintings of trees, our concepts about MS are evolving, and research in MS remains a “work in progress” (see <xref ref-type="fig" rid="fig10-1352458512470730">Figure 10</xref>).</p>
<fig id="fig10-1352458512470730" position="float">
<label>Figure 10.</label>
<caption>
<p>Past and present members of the Steinman Lab, October 22, 2011, ECTRIMS Amsterdam, NL.</p>
</caption>
<graphic xlink:href="10.1177_1352458512470730-fig10.tif"/></fig>
</sec>
</body>
<back>
<ack><p>We acknowledge the tremendous insights we have learned from the courageous individuals who live with MS and from our colleagues all over the world. We appreciate the support and dedication of our families, and the financial support in these times from governmental and private sources. Funding for medical research, considered an “entitlement” by the US government, is a necessity, and we all benefit from the fruits of these investigations.</p></ack>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p></fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512470730">
<label>1.</label>
<citation citation-type="other"><article-title>Pier Mondrian, AVOND (evening): The Red Tree</article-title>, <year>1912</year>.</citation>
</ref>
<ref id="bibr2-1352458512470730">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orton</surname><given-names>SM</given-names></name>
<name><surname>Herrera</surname><given-names>BM</given-names></name>
<name><surname>Yee</surname><given-names>IM</given-names></name>
<etal/></person-group>. <article-title>Sex ratio of multiple sclerosis in Canada: A longitudinal study</article-title>. <source>Lancet</source> <year>2006</year>; <volume>5</volume>: <fpage>932</fpage>–<lpage>936</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512470730">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noonan</surname><given-names>CW</given-names></name>
<name><surname>Kathman</surname><given-names>SJ</given-names></name>
<name><surname>White</surname><given-names>MC</given-names></name>
</person-group> <article-title>Prevalence estimates for MS in the United States and evidence of an increasing trend for women</article-title>. <source>Neurology</source> <year>2002</year>; <volume>58</volume>: <fpage>136</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512470730">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dunn</surname><given-names>S</given-names></name>
<name><surname>Ousman</surname><given-names>S</given-names></name>
<name><surname>Sobel</surname><given-names>RA</given-names></name>
<etal/></person-group>. <article-title>Peroxisome proliferator-activated receptor (PPAR)-<bold>α</bold> expression in T cells mediates gender differences in development of T cell-mediated autoimmunity</article-title>. <source>J Exp Med</source> <year>2007</year>; <volume>204</volume>: <fpage>321</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512470730">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lovett-Racke</surname><given-names>AE</given-names></name>
<name><surname>Hussain</surname><given-names>RZ</given-names></name>
<name><surname>Northrop</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Peroxisome proliferators-activated receptor α agonists as therapy for autoimmune disease</article-title>. <source>J Immunol</source> <year>2004</year>; <volume>172</volume>: <fpage>5790</fpage>–<lpage>5798</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512470730">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>MA</given-names></name>
<name><surname>Rego</surname><given-names>D</given-names></name>
<name><surname>Moshkova</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Peroxisome proliferator-activated receptors (PPAR)-α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2012</year>; <volume>109</volume>: <fpage>9505</fpage>–<lpage>9510</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512470730">
<label>7.</label>
<citation citation-type="other"><collab>Piet Mondrian</collab>, <article-title>The Grey Tree</article-title>, <year>1911</year>.</citation>
</ref>
<ref id="bibr8-1352458512470730">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chabas</surname><given-names>D</given-names></name>
<name><surname>Baranzini</surname><given-names>S</given-names></name>
<name><surname>Mitchell</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease</article-title>. <source>Science</source> <year>2001</year>; <volume>294</volume>: <fpage>1731</fpage>–<lpage>1735</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512470730">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lock</surname><given-names>C</given-names></name>
<name><surname>Hermans</surname><given-names>G</given-names></name>
<name><surname>Pedotti</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis</article-title>. <source>Nat Med</source> <year>2002</year>; <volume>8</volume>: <fpage>500</fpage>–<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512470730">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>MH</given-names></name>
<name><surname>Hwang</surname><given-names>S</given-names></name>
<name><surname>Roy</surname><given-names>DB</given-names></name>
<etal/></person-group>. <article-title>Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets</article-title>. <source>Nature</source> <year>2008</year>; <volume>451</volume>: <fpage>1076</fpage>–<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512470730">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>MH</given-names></name>
<name><surname>Lundgren</surname><given-names>DH</given-names></name>
<name><surname>Jaiswal</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Janus-like opposing roles of CD47 in autoimmune brain inflammation</article-title>. <source>J Exp Med</source> <year>2012</year>; <volume>209</volume>: <fpage>1325</fpage>–<lpage>1334</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512470730">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kanter</surname><given-names>J</given-names></name>
<name><surname>Narayana</surname><given-names>S</given-names></name>
<name><surname>Ho</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Lipid microarrays identify key mediators of autoimmune brain inflammation</article-title>. <source>Nat Med</source> <year>2006</year>; <volume>12</volume>: <fpage>138</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512470730">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>P</given-names></name>
<name><surname>Kanter</surname><given-names>J</given-names></name>
<name><surname>Johnson</surname><given-names>AM</given-names></name>
<etal/></person-group>. <article-title>Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation</article-title>. <source>Sci Transl Med</source> <year>2012</year>; <volume>4</volume>: <fpage>137ra73</fpage>.</citation>
</ref>
<ref id="bibr14-1352458512470730">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhat</surname><given-names>R</given-names></name>
<name><surname>Axtell</surname><given-names>R</given-names></name>
<name><surname>Mitra</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Inhibitory role for GABA in autoimmune inflammation.</article-title> <source>Proc Natl Acad Sci U S A</source> <year>2010</year>; <volume>107</volume>: <fpage>2580</fpage>–<lpage>2585</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512470730">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ousman</surname><given-names>SS</given-names></name>
<name><surname>Tomooka</surname><given-names>BH</given-names></name>
<name><surname>van Noort</surname><given-names>JM</given-names></name>
<etal/></person-group>. <article-title>Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination</article-title>. <source>Nature</source> <year>2007</year>; <volume>448</volume>: <fpage>474</fpage>–<lpage>479</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512470730">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ransohoff</surname><given-names>RM</given-names></name>
</person-group> <article-title>Inflammatory disease: Assault on the guardian</article-title>. <source>Nature</source> <year>2007</year>; <volume>448</volume>: <fpage>421</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512470730">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rothbard</surname><given-names>JB</given-names></name>
<name><surname>Kurnellas</surname><given-names>MP</given-names></name>
<name><surname>Brownell</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Therapeutic effects of systemic administration of the chaperone alpha B crystallin associated with binding proinflammatory plasma proteins</article-title>. <source>J Biol Chem</source> <year>2012</year>; <volume>287</volume>: <fpage>9708</fpage>–<lpage>9721</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512470730">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurnellas</surname><given-names>MP</given-names></name>
<name><surname>Brownell</surname><given-names>SE</given-names></name>
<name><surname>Su</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitis</article-title>. <source>J Biol Chem</source> <year>2012</year>; <volume>287</volume>: <fpage>36423</fpage>–<lpage>36434</lpage>. Epub <day>6</day> <month>September</month> <year>2012</year>.</citation>
</ref>
<ref id="bibr19-1352458512470730">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Noort</surname><given-names>JM</given-names></name>
<name><surname>van Sechel</surname><given-names>AC</given-names></name>
<name><surname>Bajramovic</surname><given-names>JJ</given-names></name>
<etal/></person-group>. <article-title>The small heat shock protein αB crystallin as a candidate autoantigen in MS</article-title>. <source>Nature</source> <year>1995</year>; <volume>375</volume>: <fpage>798</fpage>–<lpage>801</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512470730">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group> <article-title>Presenting an odd autoantigen</article-title>. <source>Nature</source> <year>1995</year>; <volume>375</volume>: <fpage>739</fpage>–<lpage>740</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512470730">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pangratz-Fuehrer</surname><given-names>S</given-names></name>
<name><surname>Kaur</surname><given-names>K</given-names></name>
<name><surname>Ousman</surname><given-names>SS</given-names></name>
<etal/></person-group>. <article-title>Functional rescue of experimental ischemic optic neuropathy with αB-crystallin</article-title>. <source>Eye (Lond)</source> <year>2011</year>; <volume>25</volume>: <fpage>809</fpage>–<lpage>817</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512470730">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arac</surname><given-names>A</given-names></name>
<name><surname>Brownell</surname><given-names>SE</given-names></name>
<name><surname>Rothbard</surname><given-names>JB</given-names></name>
<etal/></person-group>. <article-title>Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2011</year>; <volume>108</volume>: <fpage>13287</fpage>–<lpage>13292</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512470730">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Velotta</surname><given-names>JB</given-names></name>
<name><surname>Kimura</surname><given-names>N</given-names></name>
<name><surname>Chang</surname><given-names>SH</given-names></name>
<etal/></person-group>. <article-title>αB-crystallin improves murine cardiac function and attenuates apoptosis in human endothelial cells exposed to ischemia-reperfusion</article-title>. <source>Ann Thorac Surg</source> <year>2011</year>; <volume>91</volume>: <fpage>1907</fpage>–<lpage>1913</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512470730">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grant</surname><given-names>JL</given-names></name>
<name><surname>Bou Ghosn</surname><given-names>EE</given-names></name>
<name><surname>Axtell</surname><given-names>RC</given-names></name>
<etal/></person-group>. <article-title>Unexpected therapeutic benefit from peripheral administration of amyloid-β in TH1 and TH17 versions of experimental autoimmune encephalomyelitis</article-title>. <source>Sci Transl Med</source> <year>2012</year>; <volume>4</volume>: <fpage>145ra105</fpage>.</citation>
</ref>
<ref id="bibr25-1352458512470730">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinger</surname><given-names>JG</given-names></name>
<name><surname>Davies</surname><given-names>P</given-names></name>
<name><surname>Acker</surname><given-names>CM</given-names></name>
<etal/></person-group>. <article-title>Mice devoid of Tau have increased susceptibility to neuronal damage in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis</article-title>. <source>J Neuropathol Exp Neurol</source> <year>2012</year>; <volume>71</volume>: <fpage>422</fpage>–<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512470730">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gourdain</surname><given-names>P</given-names></name>
<name><surname>Ballerini</surname><given-names>C</given-names></name>
<name><surname>Nicot</surname><given-names>AB</given-names></name>
<etal/></person-group>. <article-title>Exacerbation of experimental autoimmune encephalomyelitis in prion protein (PrPc)-null mice: Evidence for a critical role of the central nervous system</article-title>. <source>J Neuroinflammation</source> <year>2012</year>; <volume>9</volume>: <fpage>25</fpage>.</citation>
</ref>
<ref id="bibr27-1352458512470730">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Corrigan</surname><given-names>F</given-names></name>
<name><surname>Vink</surname><given-names>R</given-names></name>
<name><surname>Blumbergs</surname><given-names>PC</given-names></name>
<etal/></person-group>. <article-title>sAPPα rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury</article-title>. <source>J Neurochem</source> <year>2012</year>; <volume>122</volume>: <fpage>208</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512470730">
<label>28.</label>
<citation citation-type="other"><article-title>Piet Mondrian, The Flowering Apple Tree</article-title>, <year>1912</year>.</citation>
</ref>
<ref id="bibr29-1352458512470730">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>DMK</given-names></name>
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group> <article-title>Uptake of gamma-aminobutyric acid in the goldfish retina</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1971</year>; <volume>68</volume>: <fpage>2777</fpage>–<lpage>2781</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512470730">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Axtell</surname><given-names>RC</given-names></name>
<name><surname>de Jong</surname><given-names>BA</given-names></name>
<name><surname>Boniface</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>T helper type 1 and 17 cells determine efficacy of IFN-β in multiple sclerosis and experimental encephalomyelitis</article-title>. <source>Nature Med</source> <year>2010</year>; <volume>16</volume>: <fpage>406</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512470730">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bushnell</surname><given-names>SE</given-names></name>
<name><surname>Zhao</surname><given-names>Z</given-names></name>
<name><surname>Stebbins</surname><given-names>CC</given-names></name>
<etal/></person-group>. <article-title>Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing–remitting MS</article-title>. <source>Neurology</source> <year>2012</year>; <volume>79</volume>: <fpage>531</fpage>–<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512470730">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hartung</surname><given-names>HP</given-names></name>
<name><surname>Steinman</surname><given-names>L</given-names></name>
<name><surname>Goodin</surname><given-names>DS</given-names></name>
<etal/>
</person-group>. <article-title>IL-17F Does Not Predict Response to Interferon-Ä in Multiple Sclerosis Patients</article-title>. <source>Arch Neurol</source> <year>2012</year> in press.</citation>
</ref>
<ref id="bibr33-1352458512470730">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>LF</given-names></name>
<name><surname>Axtell</surname><given-names>R</given-names></name>
<name><surname>Tu</surname><given-names>GH</given-names></name>
<etal/></person-group>. <article-title>IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis</article-title>. <source>Sci Transl Med</source> <year>2011</year>; <volume>3</volume>: <fpage>93ra68</fpage>.</citation>
</ref>
<ref id="bibr34-1352458512470730">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sweeney</surname><given-names>CM</given-names></name>
<name><surname>Lonergan</surname><given-names>R</given-names></name>
<name><surname>Baseo</surname><given-names>SA</given-names></name>
<etal/></person-group>. <article-title>IL-27 mediates the response to IFN-b therapy in multiple sclerosis patients by inhibiting Th17 cells</article-title>. <source>Brain Behav Immun</source> <year>2011</year>; <volume>25</volume>: <fpage>1170</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512470730">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dhib-Jalbut</surname><given-names>S</given-names></name>
<name><surname>Sumandeep</surname><given-names>S</given-names></name>
<name><surname>Valenzuela</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study</article-title>. <source>J Neuroimmunol</source>. Epub ahead of print <day>18</day> <month>September</month> <year>2012</year>. DOI: <pub-id pub-id-type="doi">10.1016/j.jneuroim. 2012.08.012</pub-id>.</citation>
</ref>
<ref id="bibr36-1352458512470730">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yednock</surname><given-names>T</given-names></name>
<name><surname>Cannon</surname><given-names>C</given-names></name>
<name><surname>Fritz</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin</article-title>. <source>Nature</source> <year>1992</year>; <volume>356</volume>: <fpage>63</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512470730">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group> <article-title>Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab</article-title>. <source>Nat Rev Drug Discov</source> <year>2005</year>; <volume>4</volume>: <fpage>510</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512470730">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group> <article-title>The discovery of natalizumab, a potent therapeutic for multiple sclerosis</article-title>. <source>J Cell Biol</source> <year>2012</year>; <volume>199</volume>: <fpage>413</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512470730">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudick</surname><given-names>R</given-names></name>
<name><surname>Polman</surname><given-names>C</given-names></name>
<name><surname>Clifford</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Natalizumab: Bench to bedside and beyond</article-title>. <source>Arch Neurol</source>. Epub ahead of print <day>5</day> <month>November</month> <year>2012</year>; <fpage>1</fpage>–<lpage>11</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamaneurol.2013.598</pub-id>.</citation>
</ref>
<ref id="bibr40-1352458512470730">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorelik</surname><given-names>L</given-names></name>
<name><surname>Lerner</surname><given-names>M</given-names></name>
<name><surname>Bixler</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Anti-JC virus antibodies: Implications for PML risk stratification</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>295</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512470730">
<label>41.</label>
<citation citation-type="other"><article-title>Piet Mondrian, Composition Trees II</article-title>, <year>1912</year>.</citation>
</ref>
<ref id="bibr42-1352458512470730">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Calabresi</surname><given-names>PA</given-names></name>
<etal/></person-group>. <article-title>Ocrelizumab in relapsing–remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial</article-title>. <source>Lancet</source> <year>2011</year>; <volume>378</volume>: <fpage>1779</fpage>–<lpage>1787</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512470730">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Coles</surname><given-names>AJ</given-names></name>
<name><surname>Arnold</surname><given-names>DL</given-names></name>
<etal/></person-group>. <article-title>Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: A randomised controlled phase 3 trial</article-title>. <source>Lancet</source>. Epub ahead of print <day>31</day> <month>October</month> <year>2012</year>. DOI:<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61769-3</pub-id>.</citation>
</ref>
<ref id="bibr44-1352458512470730">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>R</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Arnold</surname><given-names>DL</given-names></name>
</person-group> <article-title>Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2012</year>; <volume>367</volume>: <fpage>1098</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr45-1352458512470730">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fox</surname><given-names>RJ</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Phillips</surname><given-names>T</given-names></name>
</person-group> <article-title>Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2012</year>; <volume>367</volume>: <fpage>1087</fpage>–<lpage>1097</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512470730">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Platten</surname><given-names>M</given-names></name>
<name><surname>Youssef</surname><given-names>S</given-names></name>
<name><surname>Hur</surname><given-names>EM</given-names></name>
<etal/></person-group>. <article-title>Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2009</year>; <volume>106</volume>: <fpage>14948</fpage>–<lpage>14953</lpage>.</citation>
</ref>
<ref id="bibr47-1352458512470730">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stegbauer</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>D</given-names></name>
<name><surname>Seubert</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2009</year>; <volume>106</volume>: <fpage>14942</fpage>–<lpage>14947</lpage>.</citation>
</ref>
<ref id="bibr48-1352458512470730">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Youssef</surname><given-names>S</given-names></name>
<name><surname>Stüve</surname><given-names>O</given-names></name>
<name><surname>Patorroyo</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease</article-title>. <source>Nature</source> <year>2002</year>; <volume>420</volume>: <fpage>78</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr49-1352458512470730">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waubant</surname><given-names>E</given-names></name>
<name><surname>Pelletier</surname><given-names>D</given-names></name>
<name><surname>Mass</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>1171</fpage>–<lpage>1178</lpage>.</citation>
</ref>
<ref id="bibr50-1352458512470730">
<label>50.</label>
<citation citation-type="web"><collab>Transparency Life Sciences</collab>, <ext-link ext-link-type="uri" xlink:href="http://transparencyls.com">http://transparencyls.com</ext-link> (<year>2012</year>, <access-date>accessed 12 November 2012</access-date>).</citation>
</ref>
<ref id="bibr51-1352458512470730">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lutterotti</surname><given-names>A</given-names></name>
<name><surname>Sospedra</surname><given-names>M</given-names></name>
<name><surname>Martin</surname><given-names>R</given-names></name>
</person-group> <article-title>Antigen-specific therapies in MS — Current concepts and novel approaches</article-title>. <source>J Neurol Sci</source> <year>2008</year>; <volume>274</volume>: <fpage>18</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr52-1352458512470730">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabatos-Peyton</surname><given-names>CA</given-names></name>
<name><surname>Verhagen</surname><given-names>J</given-names></name>
<name><surname>Wraith</surname><given-names>DC</given-names></name>
</person-group> <article-title>Antigen-specific immunotherapy of autoimmune and allergic diseases</article-title>. <source>Curr Opin Immunol</source> <year>2010</year>; <volume>22</volume>: <fpage>609</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr53-1352458512470730">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juryńczyk</surname><given-names>M</given-names></name>
<name><surname>Walczak</surname><given-names>A</given-names></name>
<name><surname>Jurewicz</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Immune regulation of multiple sclerosis by transdermally applied myelin peptides</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>593</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr54-1352458512470730">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bar-Or</surname><given-names>A</given-names></name>
<name><surname>Vollmer</surname><given-names>T</given-names></name>
<name><surname>Antel</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial</article-title>. <source>Arch Neurol</source> <year>2007</year>; <volume>64</volume>: <fpage>1407</fpage>–<lpage>1415</lpage>.</citation>
</ref>
<ref id="bibr55-1352458512470730">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garren</surname><given-names>H</given-names></name>
<name><surname>Robinson</surname><given-names>W</given-names></name>
<name><surname>Krasulová</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Phase 2b trial of a DNA vaccine encoding myelin basic protein in relapsing multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2008</year>; <volume>63</volume>: <fpage>611</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr56-1352458512470730">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tradtrantip</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Saadoun</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Anti-aquaporin-4 antibody blocker therapy for neuromyelitis optica</article-title>. <source>Ann Neurol</source> <year>2012</year>; <volume>71</volume>: <fpage>314</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr57-1352458512470730">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinman</surname><given-names>L</given-names></name>
<name><surname>Zamvil</surname><given-names>SS</given-names></name>
</person-group> <article-title>Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica</article-title>. <source>Ann Neurol</source> <year>2012</year>; <volume>71</volume>: <fpage>287</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr58-1352458512470730">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group> <article-title>Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity</article-title>. <source>J Intern Med</source> <year>2010</year>; <volume>267</volume>: <fpage>441</fpage>–<lpage>451</lpage>.</citation>
</ref></ref-list>
</back>
</article>